The funds will be utilised to advance the development of its platform to rapidly meet the requirement for cognitive screenings and insights
Digital health company Linus Health has secured $55m in Series B financing to boost the growth of cognitive screening technology for early detection of Alzheimer’s disease.
The company will use the funds to expand its team as well as to advance the development of its platform to rapidly meet the requirement for cognitive screenings and insights.
Its platform provides a noninvasive and time-efficient method for the evaluation of cognitive health, including pre-symptomatic detection of cognitive impairment.
The latest funding is said to follow a series of studies, which validate the efficacy of the Linus platform in identifying cognitive diseases.
Linus platform and assessments such as DCTclock digital clock-drawing test have been used by researchers to detect the beginnings of Alzheimer’s disease pathology in their studies.
The DCTclockTM digital clock-drawing test is a Food and Drug Administration (FDA) registered Class II medical device for cognitive assessment.
In a study from researchers at Massachusetts General Hospital (MGH), the platform is said to have demonstrated to be highly effective in detecting signs of early Alzheimer’s disease.
In addition, the platfrom is also being assessed in a larger study carried out by the Global Alzheimer’s Platform Foundation (GAP).
Linus Health CEO David Bates said: “Linus’s multimodal digital tools are designed to be easily scalable and accessible, lowering the cost of care dramatically while detecting symptoms earlier than traditional testing, and at the most ideal time for intervention.
“Early detection is the first step in addressing cognitive decline, and Linus Health is providing the foundation to deliver screening and specialist insights into primary care globally.”
Linus’ multimodal, smartphone or tablet-based brain health solution allows to collect objective data from multiple digital measures of cognitive and motor function. The data is translated into actionable insights.
The solution enables care professionals to monitor brain health remotely over extended periods of time.